ƓᛅƢǔƜƱ

2012!7"7!#
2012!7"7#
CSP"HOR!$ Ǩȓȇȳǹ
ᲴƭƘǔȷƭƨƑǔȷƭƔƏ%&'()*+,

 '$/ƔǒᚮၲǬǤȉȩǤȳǁ žǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷॖ࣬ൿ‫ܭ‬-./0/0120345
6$78209:;78<=0>?
@A7B ʻࢸƷᛢ᫆Ჴधᎍȷ‫׎‬ൟȷᅈ˟ƷᙻໜƔǒ
धᎍ
ᅈ˟ ᙻໜ
2

3

EBM: evidence"based medicine
EBM:!evidence"based!medicine• CDEFGH2I“LANDMARKS”• JKLMNOPQRSTUH50VUCD
WXYZ[\](^_`abc2Id eeef

• ghijukvulmwukxlwyz{lk|xu
ghij k lm k llk
G. Guyatt,y R. Drummond, et al.
The Users’ Guides to the Medical Literatureseries in JAMA, 1992~2000

3David L Sackett, et al. Evidence-based
medicine: What it is and what it is not.
not
BMJ 1996;312:71-72 (13 January)

–|}
–|}u

~wvl zwvw{zm wkwxw~wvluzwvw{zmuwkwxw–klmu kxk{uwwzlkvwu
–{xuu {lkwxlu{wv
•nopqrst0V
Ss N

^UNQR
N^
Weerss ,V]Wghkwxw~{vwujwkkxw |ul|uz{lkwu{xulw{muhij¡u¢{£wll wlu{¤uij¥u¦§§¨u]4

4

2IE©ª,«¬­®

EBM (2011)(Muir!Gray,!Evidence"Based!Healthcare,!2nd!Edition,!2001!)!

• Evidence!based"medicine"(EBM)"E idb ddi i (EBM)
requires the integration of the bestrequires"the"integration"of"the"best"
research"evidence"with"clinical"
expertise"and"our"patient’s"unique"values and"circumstances.

ValuesW¯°e±²]

Evidence,-./0+

their"individual"clinical"state"
and"the"clinical"setting
d h l
l
5

Resources!"#$ %
W³´µne¶e&'()''*+

6

EBM123456789:'''• ;<=9 Professionalism• >?=9 Integrity

1. BCDEF<G9HI
J1KLMCNOPQR
ST9UVJ
2. WX9,/YZ[/\9]^:_` ab]^:_`3ab9,/
YZ[/\1]^3Ec
3. de7Tfg4hi;<
hjk l=1m34c
hjknl=1m34c
8opJ• @A9 Maturationi7

8

KL;Tg49,-./0
KL;Tg49-./0,-./09rst

ueiuvR''',-./0,-./0
wx+yz{;<u8R|} ~+



u8R

uei

>?
uvR
vR

+
9

EBMAg4nKL;T34
i6g8e 9 1997+ ;+9BC1`nNRi
Eg8 !BC9" ¡¢c4£RST1¤9¥¥¦§RiE)¨c13vvE 8 !©ªD«¬9­®")¨c13vvEg8r¯°±²³¢e78F<n´9;µe¶·r¯±²³¢e78F<n´9;µe¶·678F<T¥¶`nwx9£RF<1¸QiEg8 !wx9¹º"»$9¼½u8¾,-./01¿À38
cTÁRiEg8Á!>?Ä9ÂÃ"?
ÂÃ

KL;T34ÅÆ1ÇÈ8>?ÉÊ[YË[/!"#$%!&''()* +,-.)• ÌÍÌÍÕÖ×ØÙÍÚÎÏÐÙÚÑÛÜÜÝÞßÚÒÛÏÍÙÚÎÏ×ÙÚÓÔÔÔÍ ÎÏÐ ÑÒ ÏÍ ÎÏ ÓÔÔÔ• S9ànáâ:§¾ãäNaäåDEæçèéêëìkíîï7n!åðñaòóôõ9Çök_VTEg8 ,-./0:÷ER!åðñaòóôõ9Çök_VTEg8ø,-./0:÷ERùúN:Ev@ADEûçüý/\ï¿§ïRø• ÑÛÞÕÏÕÏ×þÚÚÑÙÜÿÏÿÚÚ Ö!ÜÖÏþ×ÚÚþÛÏÍÙ"Ï×ÙÿÚÚÐÝÞÚ!Ö×ÖþÙ!Ù×ßÚÚÚÝÐÚ
ÿÙÕÙÞÙÚÿÙÜÿÏÿÚÚÖ×ÍÚÚÿÙÜßÏØÚÚÿ#ÝØ$%Ú ÞÏß ÖÞÙÚÚ&ÙÍ ÓÔÔ'(ÚÚ)Ó*+,+Ú-.)• S9à!":#$%!&'()*+,-./0123456789;/01!&'()*+,-./0123456789• <==>==?>@ABCDBAE>BFGH@HFIGB>DD>FAHJ>@>==BCDBKLG?C@IMNBIMA>MNB
FIAE>A>M= H@ ?I@IO>?>@A CD KIAH>@A= H@ H@A>@=HJ> FIM> PQ<RS
FIAE>A>M=BH@B?I@IO>?>@ABCDBKIAH>@A=BH@BH@A>@=HJ>BFIM>BPQ<R
TI@UVBIBMI@WC?H=>W FC@AMCGG>WBAMHIGXBYI@F>ABZ[[\]^__V`aZSaX• bcdedf6ghgi-jklmnoprstuv'wn:x!yzrn{|}~12;muv!EBMmmuv !-'s  sw ;Evidence based Medicine!
 7c -
h7ch-
Evidence based clinical
decision making)lEvidence)! ¡Preference)¢Clinical¢£¤Expertise)
ExpertiseH6[1993]µ¶ ·l¸¹¦º,m»• ¼½¾v¿À2wt!nvtÁ'• ¿À2¬­®db!ÂÃr-Ä~

.Patientpreference¯b5¬­®db-Åw»
Reserch
Evidence¢s¥¡¦§¨vw n ;l©ª«w§ª-';«¬­®db!¯i°±n²w s't³´w ;Ø"!)ÙÚd5Ûhi
• 2000µRCT ÜÝ0Þdbßd,à#$%4áâã
– ! Ý0Þdbßd,àsäå
• 2008µRCT ÜÝ0Þdbßd,à#$%æç¨è:é)Ùßbêëã– ! Ý0Þdbßd,àsìí
• 2009µSR ÜÝ0Þdbßd,àØ"îïðßbÝ0Þdbßd,àØ"îïðßb-éñ¨èã
– ! ìí!««• 2009µSR ÜÝ0Þdbßd,à#$%éñã
– ! Ý0Þdbßd,àsòä

• EBM-¼Æ:ÇÈ:ÉÊsËÌÍyÎÏ
• EBM!ÐÑ-ÒÓ¾vÔÕÖ×À'óôõ37öªwm!÷Ûøùúûüßý7
þmÿ ! (American!College!of!Physicians!!2002)• ÷Ûøùúûüi¾v!"#!$%
÷Ûøùúûüi¾v! #!$%
A Set of Professional Responsibilities»
1. ÷Ûøùúûüi¾v!&Æ'w$%
commitment!"#$%&'()*+,!"./0123+,!"456789:0;<3+,=> ?0@ B +,=>5?0@ABC+,=>D5EFGH0@ABC+,IJ5=>KL56'MN#93+,OPQ8RS#93+,TOPQUV#WXY=>0Z[,9 \]^_#67#$`%&ab0;<3+,9.
10. cdefghijkTlmn 5,o0pr3,2.
3
3.
4.
5.
6.
7.
8.

st

POEMs

BMJ’ss “killer”
BMJ
killer question
Joint workshop with BMJ at the WONCA
2005, Kyoto• If thi
this studyt d isi “true”“t ” would
ld it beb a
POEM (Patient Oriented Evidence
that Matters)?
• If it wouldn’t, move on• You
Y willill probably
b bl beb ablebl tot discarddid
70% of studies with this question
alone

17

=P5OP =P5OP

• Patient
Patient-orientedoriented evidence that matters.
mattersq”vwxyH”z{7|)}8Y• Shaughnessy AF, Slawson
DC.
q”!"B~#4&5*+vwxyH”z{7|POEMs: patient-oriented
evidence thatmatters. Ann Intern Med. 1997;126:667• “.. we need to adopt the goal that medicine must
provideid care thath hhas bbeen shown,hthroughhhactual study, to help patientsli longer,
livelhealthier,h l hi more productive,d isymptom-free lives.”§¨©P5/#93+ª«§¨©P / 93 ª«
1979• research!ethics!
research ethics T
–research!ethicsT• $#+""–research!integrity
research integrity• OPD5B4 '8¡¢OP
• scientific!misconductT£'Z¤• publication!ethicsT¥¦• conflict!of!interestT\]^_• “Scientifically valid, ethically soundsound”(CONSORT!group)

q!"B~#4&5*+|z
q!"B~#4&5*+|z
67#Z /B+4z{718¬­=P®¯°±²³´µ¶1¦TICMJE·¸¹=P®¯º»"¼½¾

1990

Haynes¿ÀÁÂÃÄ5ª«1991

Guyatt EBM5ª«

1992!!

ÅFÆyÇÈÉÊ5ËÌ

1996

CONSORTÍÎTRCT/
ÍÎT
/

1999

QUOROMÍÎ (ÏÐEjÑhH/)2000

MOOSEÍÎ TÒÓ5ÏÐTÒÓ5ÏÐEjÑhH/EjÑhH/

2001

CONSORTÍÎT¶2¦ ,!AGREE!instrument!TÔÕÖÆÕy×Ø

2003
STARD!InitiativeTÙÚ5/ ,!COGSª«TÔÕÖÆÕy5ÛÜ STRICTA
TÝÞ5§¨ß5/ 
2004
TRENDÍÎT àá¬QÒÓ5/ ,!GRADEª«TÙ>ÔÕÖÆÕy#+âãäåæ ,,!ICMJE#ç+§¨ßèÄ5ª«,§¨ßèÄ#93+éÐêëì+§¨ß Ä ª«,§¨ß Ä 93+éÐì
2007!STROBEÍÎTÒÓ
2009!STREGAÍÎ (íîï^9ðñ),! PRISMAÍÎT QUOROMÍÎ ò¡¦
2010!!CONSORTÍÎT¶3¦ ,!AGREE!instrument!II!TÔÕÖÆÕy×Ø

1920§¨ßèÄ
• =P®¯º»"¸¹¾óTôõö÷øõùöúûõùüýþûÿÿúöö÷÷ýû
!!"#$%&'()*+,%&'-"#.)+/0'12 (-345 (678Í– 9:;<=>?@ABCDEFGHIJKLM6
NO;?@>PQ– RSTTUVWXYZ[\C]^_?@`abPJKL
McDde6f_?@bgC?@>Ph4i;jk
lm6nopq4>PQ•

r+&!s%t(!+#$'rv'!.'%&w'5 ('STTUx'yyT0'zU{t|v'12 (-w'(} }w'STT~xSzSYY0Yy{yt~w• 78– 2004V10X6 `– ]^_]^_C>P;=>=C>P;=>=IJKLMgF=;
21

JKLM?@6R¿i• Viergever RF,
RF Ghersi D (2011).
(2011) The Quality of Registration ofClinical Trials. PLoS ONE 6(2): e14701.
doi:10.1371/journal.pone.0014701
jp• 2008V6X!2009V6XCICTRPC?@À=JKLMGFÁÂ
;ÃÄÅ731LM3• ÆÇ[È`ÉÊ?@°aËC?@Q• ÌÍÎÏ_cÐÑ[ÒLM94ÂÐÑLM54Â`Ó8Q
Ì ÎÏ_cÐÑ[ÒLM
ÐÑLM
`Ó8Q
• Ô¼ÕÖ×ØÙGÚÛÜÝ ÐÑ[Ò 77%ÐÑ 57%• ÞßàcÜÝgc>áâãäQ
• Þßàåæçèéêëìíîï6cðîñQ
• 36436Ö¹òóô6õö÷ø6EPùçú4«Cûü
36436Ö¹òóô6õö ÷ø6EPùçú4«CûüÀâñ=6c35%Q
23

2003V10X¡¢£¤6¥¦C§¨P©ª6«¬;­® JKLM6?@4¯6«¬;­®QJKLM6?@4¯°;WHO6±¤4²³´¨PQµ¶JKLM?@·¸¹º»¼(International Clinical Trials Registry Platform:
ICTRP)·½¾ ¹°aQ

22

ýþÿ

ÅCOI3 6ü!µ Institute of Medicine Å20093
Å
3“A
A conflict of interest is a set of circumstancesthat creates a risk that professional judgment
or actions regarding a primary interest will be
unduly influenced by a secondary interest.”
COIîB"C§¨P#$Ó%&'(` )îB"ýþC*+â,Ï'(`)îB"
ýþC*+â,Ï
C-.ÀP/Ù ;0HP12Q
http://iom.edu/CMS/3740/47464/65721.aspx‫‥׋‬Ўᅹ˟↚ⅹↀ↺‵⁁※ሥྸ↝̊

ࢫՃሁ
45Gp
q´B4
5

,L=Mâ
JICDE

67ù
COI

°ä

˟Ճ≋᩼˟Ճԃ≌
?@ù
èAù
COI°ä

WebsiteCâ?@ù
89:;<=>
F _G
6H³

CDE

K=

89: CDEྸʙ˟≋ྸʙᧈ≌ʙ˟≋ ʙᧈ≌ ®IDJI
®I JI
$%&'(
ऴ‫إ‬
੩̓
ᙲᛪ

ƓᛅƢǔƜƱ Ǩȓȇȳǹ
ᲴƭƘǔȷƭƨƑǔȷƭƔƏ

 '$/ƔǒᚮၲǬǤȉȩǤȳǁ žǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷॖ࣬ൿ‫ܭ‬!"#)*+

2010,-./(0124
56789:/;Pr<=> ʻࢸƷᛢ᫆

ᅈ˟7?@ABC?@DEFGHI>

Ჴधᎍȷ‫׎‬ൟȷᅈ˟ƷᙻໜƔǒ
धᎍ
ᅈ˟ ᙻໜ

JKLMNOM1ҽဃі΁ႾƷӕǓኵǈ
EBMJKLMNOM1)ij

EBMef)gh

1997(kj 9)lm
.Knop)
vwxSybzgh(.Kno{p)|}1998(,)10)&'-./012
RSTUV

kj12lmij+qr

kj13lmij+qr

kj14lmij+qr--)%
kj15lm..*&ij+qr

7s5tu>

7s7tu>

7s4tu>

7s4tu>

7s3tu>
/

~
~Q
~
~

4567
!"#89
:;<=>
?@A
()

~
~
~

~
BC
DEFGH
>IJ
K67
()
Z[
\]^_
15&'
()*+

~
~
~G
M? Q
¡j
()

~¢
~e£¤
¥¦G
~:§¨©ª
¨«
MN
OPQ
15&'
()*+

~¬­®
,*&!
~¯°±²- '"~!"#$%. (#/16&') $()*+EBM!WRSXY+धᎍǋᚮၲǬǤȉȩǤȳƷȦȸǶȸŵƞǒƴܼଈŴʼᜱᎍǋȷȷႸႎƸžૅੲſ
TGIWNCVGQTFGTFKTGEVưƸƳƍŵܱោȷᐮ࠿ܼŵFQEVQTUƴᨂǒƳƍŵȁȸȠҔၲǛे‫ܭ‬ŵ

PQRSTUVW.KXCYX;Z[\]^_C`ab"#cd
27
27

•

$$"
23 14 # !

kj11lm
ij+qr

L$%
15&'
()*+

0
1
+

+'
,(
%

4
5
6
(
)

Minds
M

žཎ‫ܭ‬Ʒᐮ࠿ཞඞƴƓƍƯŴᢘЏƳЙૺžཎ‫ܭ‬Ʒᐮ࠿ཞඞƴƓƍƯᢘЏƳЙૺǛᘍƳƏƨǊŴᐮ࠿ܼƱधᎍǛૅੲƢǔႸႎưᲢCUUKUVRTCEVKVKQPGTCPF
RCVKGPVFGEKUKQPUᲣኒወႎƴ˺঺ƞǕ
F
Უኒወႎƴ˺঺ƞǕƨ ૨୿ſ቟‫׎‬Ҕ‫ܖ‬ᄂᆮ৑ +PUVKVWVGQH/GFKEKPGᲣ

26-./012efgh-.cdiHjklm
-.cdi
jklm
(Minds) #(q)rs-.tu12ttv#

2001,2(,)13`14)&'ab-./0cdn;opTUV

wxyz{|gh}~.PQZ

Relationship between citation counts in the third U.S. Guide to Clinical Preventive
Services and impact factors (2001) of 55 journals from which articles were cited morethan 5 times.

&'X~.PQ-|H
Hkv ¡¢)W£¤¥W¦§¨
©Wª«>Z¬ghhimpactfactors(2001)

60
60-

10 0
10.0-

JAMA, J NatlCancer Inst,,
Lancet, N Engl J
Med (4)5 0 10 0
5.0-10.0

BMJ (1)•­®¯&'°±²³´~.PQWµ¶·¢)n;¸²¹º»Z¬gh}¼½-.¾¿½WÀÁRS¸Â•ÃÄ&'~.PQWÅ·Æu>}¼½Ç
ÈÉÊËWcdÌÍ-.½WxÎ|Ïcitation counts in the U.S. Guide to Clinical Preventive Services

29

40 59
40-59

20 39
20-39

Am J Clin Nutr, Am J Med,
Circulation, Diabetes,
Di b t l i J Bone
Diabetologia,
B
Miner Res, J Clin Oncol,
Stroke (8)Rank Correlation Coefficient (Kendall)=0.24

-3.0

30

Am J Prev Med
(1)

5 19
5-19

EBMWáâã`ÞßWäåY`æçY+X
Ann Intern Med(1)
op¬ghop¬gh`èéêQëÙìíîÙ
èéê  ëÙìÙHã12ghïðñòÈó·ôDiabetesCare-.bõZ¬|0cdWö÷£-.
bõZ¬|0cdWö÷£`1
1
Arch Int Med (1)(1)
2Z¬äøù
Am J Pub Health, Cancer, J
U l O
Urol,
Osteo
t Intern
I t(4)

3.0-5.0
3.0
5.0• 201011&'ÐÑWEBMn;ÒS¸~.PQWÓÔÆu>Z¬gh• 201213&'ÕkÖ^Ö×ØÙEjÚHXÛ~.PQW¢)ÜÝÞßà¸EBMn;ÒS¸²¹º»

0
1
2
3
0
7

Am J Obstet Gynecol, Obstet
Gyn, Prev Med (3)úNakayama T, et al. JAMA 2003

Am J Epidemiol, Bone, Br
J Cancer, Int J Cancer, Inty, J
J Rad Oncol Biol Phy,Clin Microbiol, Pediatrics,
Sex Transm Dis (8)Am J Manag Care, Am J
Roentgerol, Ann Behav
Med, Arch Dermatol, ArchFam MedMed, Br J Dermatol,
Dermatol
Br J Gen Pract, Br J
Obstet Gynaecol, Br J
Radiol, Calcif Tissue Int,
CMAJ, Diabet Med, Ear
Hear, Eur Urol, J Am Acad
Dermatol, J Clin
Epidemiol, J Epidemiol
Community Health, J FamPract, J Gen Intern Med, J
Med Screen, Med J Aust,
Pediatr Clin North Am,
Urology (23)!"#$%&$'()*+(Clinical Practice Guidelines We can trust, IOM 2011)•%NKPKECN%NKPKECN2TCEVKEG)WKFGNKPGUCTGUVCVGOGPVU
2TCEVKEG )WKFGNKPGU CTG UVCVGOGPVU
VJCVKPENWFGTGEQOOGPFCVKQPU KPVGPFGFVQQRVKOK\G RCVKGPV ECTGQRVKOK\GRCVKGPVECTG–ᚮၲǬǤȉȩǤȳƱƸŴधᎍǱǢƷஇᢘ҄ǛႸႎƱƢǔਖ਼‫ڜ‬Ǜԃǉ૨୿ ƋǔႎƱƢǔਖ਼‫ڜ‬Ǜԃǉ૨୿ưƋǔŵ•6JG[
6JG[CTGKPHQTOGFD[CU[UVGOCVKETGXKGYCTG KPHQTOGF D[ C U[UVGOCVKE TGXKGYQHGXKFGPEGCPFCPCUUGUUOGPVQHVJG
DGPGHKVU CPF JCTOU QH CNVGTPCVKXG ECTG
DGPGHKVUCPFJCTOUQHCNVGTPCVKXGECTGQRVKQPU31–ᚮၲǬǤȉȩǤȳƸŴǨȓȇȳǹƷኒወႎȬȓȥȸƱŴᚮၲǬǤȉȩǤȳƸ
ȓȇȳǹƷኒወႎȬȓƱ
32˂Ʒᢠ৸ᏃƷႩƱܹƷᚸ̖ƴǑƬƯ˺঺ƞǕǔŵ

-./'0(1234.56(789:;(<=)

MNOPQRSTUV W XYOPNTZR >[\]\a[\^^MNOPQRSTUV_W`_XYOPNTZR>[\]\ [\^^#$%&$'>?@ (AB(CDE*FGH
I"(J(KL)34

http://www.iom.edu/~/media/Files/widget/systematic"review/infographic.swf

l&'046mnop9qr6s(tuvw

bc&'4.56defg>2009hij
5260

T2 z{j|w}~H”implementation science””implementation!science”

T1: xyz{j|w}~z{



3z{
z{

xyz{
55

>k

Hulley et al. Designing Clinical Research 3rd. 200736>9,

“Implementation science”• “Doing“
the thing”.
”!"• “Doing
Doing the right thing
thing”..

• …“Doing theRight Thing Right
Right”IOM (Institute of Medicine). 2008. Implementing
colorectalll cancer screening:iW
Workshopk h summary.
Washington, DC: The National Academies Press.

http://cochrane.umin.ac.jp/seminar_etc/muir960227.htm
37#$%&'()*+-./$%&' )*+-./
0evidence practice gap1
Alcohol dependence
Hip fracture
P ti ulcer
PepticlDiabetes
Low back pain
Prenatal care
Breast cancer
Cataracts

38'9:;<=>?@A

BCDE*

F;<G;&'9:;<=>?@A)HIJKLMNOPQR STTUV'9:;<=>?@A)HIJKLMNOPQRWSTTUVKirigaya D, et al. Internal Medicine, 20112)* 3456
0clinical[quality]
11%
indicator)
7 "8
23%
33%
45%
69%
73%
76%
79%
Percentage of time

E. McGlynn, et al. The Quality of Health Care Delivered to Adults in the
39
UnitedStates. N Engl J Med 2003

XY

Z[\] ^_ (`)

PSL5mg/abc

64/772 (8.3)

g ad
PSL5mg/ade

487/1596 ((30.5))fg

551/2368 (23.3)• PSL5mg/abc n=772
hE*0ij*k1
56^^ (7.3%)()
mnopq!"#$%&'(")
8* (1.0%)(1 0%)!456.789:;98!JMDC)<=:>?789@8A)• PSL5mg/ade n=1596
lE*!/0.1)+-.
0ij*k1487* (30.5%)• 23 n=2368
551* (23.3%)40ƓᛅƢǔƜƱ

,CD6EFG<HIJK Ǩȓȇȳǹ
• Medicine!is!a!science!of!uncertainty!
M di i iift i t!HIJK<LE)and!an!art!of!
and an art ofprobability!IM<NO).

ᲴƭƘǔȷƭƨƑǔȷƭƔƏ

 '$/ƔǒᚮၲǬǤȉȩǤȳǁ

!W.!Osler,!1849–1919) žǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷॖ࣬ൿ‫ܭ‬• ,C!information)DPQ!RST"UVWX)HIJK!
UVWX)HIJK!uncertainty)Y
i )Y
Z[\]<
(C Shannon 1948)(C.Shannon,!1948) ʻࢸƷᛢ᫆Ჴधᎍȷ‫׎‬ൟȷᅈ˟ƷᙻໜƔǒ
धᎍ
ᅈ˟ ᙻໜ
41

42

ǨȓȇȳǹƕଢᄩưƳƍ‫ئ‬ӳƷॖ࣬ൿ‫ܭ‬ƷؕแᲢǫȊȀȷǿǹǯȕǩȸǹᲣ• ॖ࣬ൿ‫ܭ‬ƴƓƚǔधᎍᐯ៲ƷӋьǛ̟Ƣ• ܹǛஇ‫҄ݱ‬Ƣǔ• ࢍƍ࣏ᙲࣱƕଢǒƔƳ‫ئ‬ӳƴ᧙ƠƯƷǈŴ‫ٻ‬ƖƳ‫҄٭‬ǛɼࢌƢǔ• ɧᙲƳžȩșȪȳǰſǛᢤƚǔ^_`TaUbcd,CDeXfgYhi

1. jklmno\Dpqrs\tu!potential!preventable!burden)

2. pqrs\v!potential!harms)
3. wA?!costs)
4. xy<z{!current!practice)• ႩƷɧᄩƔƳ᭗̖Ƴ৖২Ǜᢤƚǔ• ၌၏᝟ਃƕ‫ٻ‬Ɩƍཞඞƴ໰ໜǛ࢘Ưǔ• ȏǤȪǹǯǰȫȸȗƷཎКƷȋȸǺƴᣐॾƢǔ|g<}~r$UaPetitti!DB,!et!al.!Ann!Intern!Med.!200943

44

ƓᛅƢǔƜƱ Ǩȓȇȳǹ


!BMJ 20042004"ᲴƭƘǔȷƭƨƑǔȷƭƔƏ

 '$/ƔǒᚮၲǬǤȉȩǤȳǁ
• #$%&'()*+,-./0
12
D2
K
K2
T2

 žǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷǨȓȇȳǹƕ໯ƍſ‫ئ‬ӳƷॖ࣬ൿ‫ܭ‬

3456789:';-.<=>?@AC
3456789:';-.
=>?@ACEFGHEFAIJ?@LMANOPQRS
U@8QVWAEX•#$%&'YZ[\]A^_`3^!abcJb?def ʻࢸƷᛢ᫆Ჴधᎍȷ‫׎‬ൟȷᅈ˟ƷᙻໜƔǒ
धᎍ
ᅈ˟ ᙻໜ
45

gh'ijklmabcJb?
'nop*qqq
rstuvwxyz{|6J}~8Yu LMo
?~LM'Gp*• LMAmA.
• [Q Gghi'¡¢£C¤£¥¦§¨• [M£LMo©
[M£LMo©ªA«¬'5.­e8Q«¬ 5 ­ 
AA®¯` ®¯LMo'Gp*
• °o±A²³.­²³A´µ£CA¶·§¨• ¸p*k.©¹.£C¶·.­• °o!LM£º»£¼½£[m£¾¿5À GÁ £Â 5¥¦. ÀAÃÄ5GÅÆ`³Ç *²È.
¥¦.­ÀAÃÄ5GÅÆ`³Çp*²È.
• GLÃÉÊË`A'-.ÌÍ'ÎÏ.

46°oGA¥¦• Ð-.'ÑÒ5ËÌÍ£ÓÔÕ.Ö×£ÓÔÕ.ØÙAÚÛG£Â 5¥¦§¨­• Ó.AÜ^_AÝËÞß
– oAà?}@8£áâ£oã±Aäå­¾¿Aæçoæç èéoê êëoëM  ¼½æçoAææç£èéoê£êëoëM­£¼½æçoAæçQê5À5À­ìí)*îï£ðñ.­òAÖ×'óô-.AÜ5k£õöÌË´µ øÞùÔ­×'óô-.AÜ5k£õöÌË´µ÷øÞùÔ­• GLÓpÌùÔ£úûüAýA6þfÿ~ L'
Â-.!ÉÖSabcJb?"G#$üAý·½'%ß.6þfÿ~Â&abcJb?"Ì• °oVW!%'`(`` A)/5GÅÆ±A*+

Patient Involvement / Participation
Patient!Involvement!/!Participation• -1./qqqLMA^_[mM±-1./
LMA^_[mM±• -2./qqq[mA01LM!°o ±– [mA23qH®1GÜ4[mA23 H®1GÜ4– 2Ô5Ì[mVWÀÄ6p*Ëkù4– 758m¾9GÜ4!<´– 10§¨5£Ó.¹[mA:Ü;ù4– qqq

ଐஜ ȫǹ ȟଐஜȘȫǹǳȟȥȋǱȸǷȧȳᄂᆮ˟Ǳ Ƿ ȳᄂᆮ˟

°o=!"#$%&'()*+-./0123
@ABCD

50

Communicating risks and benefits:3(9 ¡¢ ~FDA 2011
1. '()#£¤&¥¦

http://www.mhlw.go.jp/topics/bukyoku/iyaku/syoku anzen/riskcom/01.html§¨Y¡©^_

2. Zª'()«¬Ro <­ª'()Y¡©^_• '()45&6789:;%<'()=>?<'()EF?<GH?<IJ?<KL?<M&
N&OP?&QR ST:UVWXYZ[9N&OP?&QR<ST:UVWXYZ[9\]^_`#a

3. ®¯&w°&4±Y²³´_®¯&w°&4±Y ²³´_
4. ²³´wµQY¶·u
5. §¨o¸¹)º»dN&-¼½o¾¬Y
5¶·u
6. ¿0(»À3#ÁÂÃ&'()#£¤&ÄÅYiÆ9^_– '()=>&bcd'()EF&efIg&hiYjka' )=> bcd' )EF efIg hiYjk

7. §¨oÇÈ<STÉYÊ¸^– OP?lmnop9qrs%tuWX\]m<vwoxy&z
fop&{9tuWX|}~;_' ) 3 l
fop&{9tuWX|}~;_')*3
&_&a

8 ËÌÍ#ÎÏÌÍÐÑ&ÒÓY¡©^_8.
9. ÔÕoST&WYÖ×_w°&Øh»¿½r
wÙ13Ú½&ÛÜYÝÞ^_– 00YwSTop&
  YwSTop&  o&;W
R&'()*+-./01239O^_}9jr_aAugust"2011."

10. ßÜà9*+-./0123Ì(Y^_52¦N§¨©ª vwA15[2003]y«{ ¬|%&'( ) *+-./ !"#$
á4&0âSTYã$ä!"#$• '­®v¯°±|• ²³´µ¶'­®v¯·±|• ¦N¸¹º»'­®v¯¼±|• ½¾'= v¯9±|• 01*+'23– 6'7$'48'9:5;
4
5– 48<=>?*+'@A#BC– DE*+KFGHI*+KEJ*+K
DE*+ FGHI*+ EJ*+LMN'O1P*+QRRR– ½¾¡K¦N'§¿'ÀV<¸f\ÁÂ#ÃÄ-Å\##Q< ¦N'§¿'ÀV<¸f\ÆÇ<?ZÈÉ\##Q<K¦N'§¿'ÀV<¸f\ÆÇ<?ZÈÉ-ÊËf\Ì!<Í\"#<ÌZK¦N'§¿'ÀVÎÏ ¢= -Ñ-ÑfQ'#f\Ò
fQ
f\Ò<ÎÏÐ¢=• 48*+STUVW-XYZ• S[\U]^_'`ab^cKS[_U??Sdef\Ugh'i1jk#lmn– SLJ*+()1-Z$Z
$_K"QQ'=$_K
QQ'= $¡¢^v£¤h¥|U• RRRSÈÉ-u!U'Ó<f"#•6Ô'*+-./ !"#• /^/K6-<Õ\<¡KÖ×RØ»RÙÚ¡KÛË¿-ÜKÝË­Þ-Ñ/Kgh c ß¡KÛË¿-ÜKÝË­Þ-Ñ/Kgh^c'ßà-ÜZ"#áâÒ

53

54– SMopqUrstuvwAxxyz{|-};ZK~@hLMNhLMN 
h-:h-:O1P56789i:ç'A;!
"# $ % &'()&

ãä¡ 0åæçè U<
ãä¡S0åæçèU<éghVê#ë'µìíî• ïºìß2011y 6{30ð(ñ)21ï24&òß!*"+-• ÚóRôõ'ghVêö©v©¥R÷øÚó ôõ'ghVêö©v©¥ ÷ø
8ùú|¡30ð'h $K• 48ûª8<48ûª8_ü\ghVê
_ü\ghVêRë'µìíîë µìíî 'ýþ-ÿ¬/Ò•ᲬᲪᲪᲳ࠰ႆឱ

JVVRJGCNVJEQOOWPKECVKQPLRJEJVO

49µìíî¡ë®Ky KLJK!WV"¢#'6&$ûK%&'%'©8À(<Qdef\Ò• Úó¡);]*+<Qh<ª--t.Ò2014y6{<íî-.// 15y1{'0e12-34f
6{<íî-.//K15y1{'0e12-34fÒ
55

./
01.
23

45
67
8923
56

:;<=>3(?17@3A
B(CDEFG02011H11IJ

'( ,L N'(C,LMNOPQRSTUVWSVEBM ¡¢£¤¥Q£¦R§¨• XYZUVW[\• ,L©) Professionalism
P f ili• ª«©) Integrity• '() Maturation– ]^– ]_`a• gH)chijkl• CCC m• nopqrstu
vw• x|osy}qsp~
x osy sz{
• sq|sp~ C
• x|s}o}sp}o '(z;• sr}
sr} VW (ethics)!

bc)def• CCCEBMEBM O¬R­®¯° ¡¢£b!")Cf- 0valueJ

57• ±²³´µU,L´µU'( ¶·¸¹¨¢£¦R)ºCCC»¼!"!"-#$%&'#$%&' ()*+,
58